STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
BCCA - Vancouver, Vancouver, British Columbia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Contact: Study coordinator (Shivani Dadwal)Kingston Health Sciences Centre, Kingston, Ontario, Canada
Contact: Study coordinator (Gordon Moffat)Waterloo Regional Health Network (WRHN), Kitchener, Ontario, Canada
Contact: Study coordinator (Anupam Batra)London Health Sciences Centre Research Inc., London, Ontario, Canada
Trillium Health Partners - Credit Valley Hospital, Mississauga, Ontario, Canada
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
University Health Network, Toronto, Ontario, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
The Jewish General Hospital, Montreal, Quebec, Canada
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
Study leads
Vincent Tam
Study Chair
Arthur J.E. Child Comprehensive Cancer Centre, Calgary AB, Canada
Jennifer Knox
Study Chair
University Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada
Marilina Piccirillo
Study Chair
NCI-Naples, Italy